Mucus therapy is one of the therapies for gastric ulcer management aside from proton pump inhibitor (PPI) and H2-blocker medication. Bioactive fraction DLBS2411 which comes from Cinnamomum burmannii has been identified as a gastric acid anti-secretory agent by inhibiting the activity of hydrogen-potassium adenosine triphosphate (H+/K+ATPase). The study was aimed to evaluate the effect of DL…
DLBS2411, a bioactive fraction of Cinnamomum burmannii, has been proven to exhibit its anti-ulcer properties through preclinical and clinical studies. However, the bioactive compounds, protein targets, and underlying molecular pathways are still poorly known. Therefore, network pharmacology was used in this study to understand the molecular mechanisms of DLBS2411 in treating gastritis. There…